Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'

Benzinga02-12 19:28

Sanofi SA (NASDAQ:SNY) on Wednesday decided not to renew the Director mandate of Paul Hudson. As a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610448940?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/12/Gentilly--France--March-21--2021-Sign-An.jpeg?optimize=medium&dpr=2&auto=webp&width=630","is_english":true,"pubTime":"2026-02-12 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610448940","market":"us","top_or_hot":-1,"title":"Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'","media":"Benzinga","content":"<div>\n<p>Sanofi SA (NASDAQ:SNY) on Wednesday decided not to renew the Director mandate of Paul Hudson.\nAs a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his ...</p>\n\n<a href=\"https://www.benzinga.com/markets/large-cap/26/02/50569675/sanofi-shocker-ceo-paul-hudson-out-as-board-demands-increased-rigor\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Shocker: CEO Paul Hudson Out As Board Demands 'Increased Rigor'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-12 19:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/large-cap/26/02/50569675/sanofi-shocker-ceo-paul-hudson-out-as-board-demands-increased-rigor><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi SA (NASDAQ:SNY) on Wednesday decided not to renew the Director mandate of Paul Hudson.\nAs a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his ...</p>\n\n<a href=\"https://www.benzinga.com/markets/large-cap/26/02/50569675/sanofi-shocker-ceo-paul-hudson-out-as-board-demands-increased-rigor\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/markets/large-cap/26/02/50569675/sanofi-shocker-ceo-paul-hudson-out-as-board-demands-increased-rigor","article_id":"2610448940","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/12/Gentilly--France--March-21--2021-Sign-An.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/large-cap/26/02/50569675/sanofi-shocker-ceo-paul-hudson-out-as-board-demands-increased-rigor","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610448940","pubTimestamp":1770895680,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Sanofi SA  on Wednesday decided not to renew the Director mandate of Paul Hudson.As a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his tenure of six years with the company.The Board of Directors appointed Belén Garijo as Chief Executive Officer. She will take up her duties at the end of the Group’s Annual General Meeting on April 29, 2026. The Board will also propose to the shareholder vote the candidacy of Belén Garijo as a director of the Group.Olivier Charmeil, Executive Vice President, General Medicines, will assume the role of Interim Chief Executive Officer during this transition.Belén Garijo will bring an increased rigor to the implementation of Sanofi’s strategy and accelerate the preparation of the Group’s future. Her priority will be to strengthen the productivity, governance, and innovation capacity of Research & Development.Reuters noted that the abrupt transition, underscoring rising pressure on Sanofi from U.S. vaccine head","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AD":"Array Digital Infrastructure Inc.","PPH":"VanEck Pharmaceutical ETF","BK4588":"碎股","BK4585":"ETF&股票定投概念","SNY":"赛诺菲安万特","SNYNF":"Sanofi","HUDAU":"Hudson Acquisition I Corp","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4132":"无线电信业务"},"translate_title":"赛诺菲令人震惊：首席执行官保罗·哈德森因董事会要求“更加严格”而辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PPH":1,"AD":1,"HUDAU":1.5,"SNY":1,"SNYNF":1.5},"content_text":"Sanofi SA (NASDAQ:SNY) on Wednesday decided not to renew the Director mandate of Paul Hudson.\nAs a result, Paul Hudson's last day as Chief Executive Officer will be on February 17, 2026, after his tenure of six years with the company.\nThe Board of Directors appointed Belén Garijo as Chief Executive Officer. She will take up her duties at the end of the Group’s Annual General Meeting on April 29, 2026. The Board will also propose to the shareholder vote the candidacy of Belén Garijo as a director of the Group.\nOlivier Charmeil, Executive Vice President, General Medicines, will assume the role of Interim Chief Executive Officer during this transition.\nBelén Garijo will bring an increased rigor to the implementation of Sanofi’s strategy and accelerate the preparation of the Group’s future. Her priority will be to strengthen the productivity, governance, and innovation capacity of Research & Development.\nReuters noted that the abrupt transition, underscoring rising pressure on Sanofi from U.S. vaccine headwinds and a stalled turnaround since Hudson took the reins in 2019 to replace blockbuster drugs.\nReuters also highlighted that Hudson had been hired with a mandate to revive the company’s drug pipeline and share price, but has struggled to reduce Sanofi’s dependence on its star eczema treatment Dupixent, drawing pressure from investors.\nDupixent sales increased by 32.2% to 4.2 billion euros in the fourth quarter of 2025, a strong end to the year.\n\"We believe that we will not be able to mitigate the impact of the (loss of exclusivity) of Dupixent as far as sales are concerned. It's too big to be mitigated,\" Sanofi's CFO François-Xavier Roger told Reuters.\nVaccine sales decreased by 2.5% to 2 billion euros from lower sales of Beyfortus and PPH, with influenza performing better than anticipated.\nBeyfortus sales were 686 million euros, down 14.9%, and Influenza, COVID-19 vaccines sales were up 31.5% to 575 million euros.\nPolio/Pertussis/Hib (PPH) primary and booster vaccines sales were down 9.5% to 551 million euros, mainly from fewer babies born in multiple countries, including China.\nSanofi is developing amlitelimab, considered a potential successor to Dupixent.\nThe company said the data delivered a robust body of evidence that supports amlitelimab’s potential in the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis (AD).\nSNY Price Action: Sanofi shares were down 6.25% at $46.17 during premarket trading on Thursday, according to Benzinga Pro data.\nPhoto by HJBC via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610448940","isCrawlerRequest":true}